AlphaLens

TERMINAL

ANALYSIS

Heatmap Stock Lists AlphaBrain Compare Track Record News Rumor Radar Calendar Macro Leaderboard ETF X-Ray Learn

MY SPACE

Dashboard Watchlist Portfolio Achievements Settings

QUICK ACCESS

AAPLApple MSFTMicrosoft NVDANVIDIA GOOGLAlphabet AMZNAmazon TSLATesla

Home Screener Watchlist Account

v12

TICKER Dashboard Screener Macro

UTC ●

LOADING MARKET DATA… │ UTC ●

Loading page…

Screener·Stocks·Lists·Heatmap·Top Picks·Deep-Dives·AlphaBrain·Track Record·Accountability·News·Rumor Radar·Compare·Learn·Free SEC Filings·Pricing·FAQ·Terms·Privacy

AlphaLens provides algorithmic financial data and pre-computed AI analysis for educational and informational purposes only. AlphaScore™, TSI™, EQS™, AlphaMomentum™, Close-vs-Gap Pressure, CER™, Volatility Regime™, Earnings Execution™, Macro Regime Detector™, Portfolio Health Engine™, and Similarity Engine™ are proprietary mathematical algorithms. No output constitutes investment advice or a guarantee of future performance. Conduct independent research. Consult a licensed financial advisor.

Biogen Inc. (BIIB)

Biogen Inc.

Healthcare

$225.71

+3.33%

nightly snapshot · 10/11/2026

ALPHASCORE™ · C+ · Watch

ALPHASCORE

/ 100

C+

WATCH

▲ 0 · 30D

KEY FUNDAMENTALS

P/E40.1

ROE7.1%

NET MARGIN13.1%

GROSS MARGIN75.7%

MKT CAP$33.35B

loading full analysis…

DAILY BRIEF

Biogen Inc. is evaluated with an AlphaScore of 55/100 in the Healthcare sector based on the 2026-10-11 snapshot. Fundamental indicators feature a strong gross margin of 75.69% and a conservative debt-to-equity ratio of 0.34. A major strength is its high momentum subscore of 84/100, tracking strong recent trading behavior. Conversely, a key risk is its poor growth subscore of 6/100, driven by minimal revenue growth of 2.22%.

Written 11/10/2026, 00:34:47 UTC · Snapshot 11/10/2026